Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Fizazi, Karim; Foulon, Stéphanie; Carles, Joan; Roubaud, Guilhem; McDermott, Ray; Fléchon, Aude; Tombal, Bertrand; Supiot, S.; Berthold, Dominik R.; Ronchin, P.; Kacsó, Gabriel; Gravis, Gwénaëlle; Calabrò, Fabio; Berdah, Jean-François; Hasbini, Ali; Silva, Marlon; Thiery‐Vuillemin, Antoine; Latorzeff, I.; Mourey, Loïc; Laguerre, Brigitte; Abadie‐Lacourtoisie, Sophie; Martin, Étienne; Kouri, Claude El; Escande, Anne; Roselló, A Soler; Magné, Nicolas; Schlürmann, Friederike; Priou, Frank; Chand-Fouché, Marie-Eve; Freixa, Salvador Villà; Jamaluddin, Muhammad; Rieger, Isabelle; Bossi, Alberto

doi:10.1016/s0140-6736(22)00367-1

Cited by 454 publications

(376 citation statements)

References 30 publications

Supporting

Mentioning

338

Contrasting

Unclassified

Order By: Relevance

“…abstracts and a yet to be indexed article [12,[24][25][26], and three abstracts with updated analyses [11,27,28] of included RCTs. During the peer review process for this article in April 2022, full-text publications of two RCTs [29,30] and an update to a third RCT [31] appeared. These publications were included but did not alter the analysis that was based on identical abstract data presented previously.…”

Section: Evidence Synthesismentioning

confidence: 99%

See 1 more Smart Citation

Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis

Roy

Sayyid

Saad

et al. 2022

European Urology Oncology

View full text Add to dashboard Cite

Section: Evidence Synthesismentioning

confidence: 99%

“…[1,2,5,6,[8][9][10][11][12][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. Overall, across these 11 RCTs, 11 546 patients were treated in one of the four treatment regimens: ADT alone (n = 4548), ADT plus ARAT (n = 3211), ADT plus docetaxel (n = 2366), and the triplet of ADT, ARAT, and docetaxel (n = 1421).…”

mentioning

confidence: 99%

Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis

Roy

Sayyid

Saad

et al. 2022

European Urology Oncology

View full text Add to dashboard Cite

“…PEACE-1 and ARASENS are recent trials that have found survival benefits to combining ARATs with chemotherapy in the mCSPC setting [ 120 , 121 ]. Novel agents, such as AR-V7 direct antagonists, were also examined in combination with ARATs as a mechanism for overcoming acquired resistance to ARATs.…”

Section: Limitationsmentioning

confidence: 99%

Emerging Biomarker-Guided Therapies in Prostate Cancer

et al. 2022

View full text Add to dashboard Cite

Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the past decade, several new treatments for advanced prostate cancer have been approved. With a wide variety of available drugs, including cytotoxic agents, androgen receptor axis-targeted therapies, and alpha-emitting radiation therapy, identifying their optimal sequencing remains a challenge. Progress in the understanding of the biology of prostate cancer has provided an opportunity for a more refined and personalized treatment selection process. With the advancement of molecular sequencing techniques, genomic precision through the identification of potential treatment targets and predictive biomarkers has been rapidly evolving. In this review, we discussed biomarker-driven treatments for advanced prostate cancer. First, we presented predictive biomarkers for established, global standard treatments for advanced diseases, such as chemotherapy and androgen receptor axis-targeted agents. We also discussed targeted agents with recent approval for special populations, such as poly ADP ribose polymerase (PARP) inhibitors in patients with metastatic castrate-resistant prostate cancer with homologous recombination repair-deficient tumors, pembrolizumab in patients with high levels of microsatellite instability or high tumor mutational burden, and prostate-specific membrane antigen (PSMA) directed radioligand theragnostic treatment for PSMA expressing tumors. Additionally, we discussed evolving treatments, such as cancer vaccines, chimeric antigen receptor T-cells (CAR-T), Bispecific T-cell engagers (BiTEs), other targeted agents such as AKT inhibitors, and various combination treatments. In summary, advances in molecular genetics have begun to propel personalized medicine forward in the management of advanced prostate cancer, allowing for a more precise, biomarker-driven treatment selection with the goal of improving overall efficacy.

show abstract

“…Second, emerging radionuclide therapies (e.g., 177 Lutetium [Lu]‐prostate‐specific membrane antigen [PSMA]) 4,5 or genomic biomarker‐directed therapies (e.g., poly [ADP‐ribose] polymerase [PARP] inhibitors) 6,7 are further crowding an already complex treatment landscape. Third, although recent phase III clinical trial data supports ARPI use early in the disease course and in combination with taxanes, 8 real‐world evidence suggests that the majority of men with metastatic castration‐sensitive prostate cancer (mCSPC) continue to be treated with androgen deprivation therapy (ADT) alone 9 . Together, these challenges mean that treatment patterns frequently differ geographically and between similarly presenting patients.…”

Section: Introductionmentioning

confidence: 99%

Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer

Kwan

Wyatt

2022

The Prostate

View full text Add to dashboard Cite

Background Genomic alterations to the androgen receptor (AR) are common in metastatic castration‐resistant prostate cancer (mCRPC). AR copy number amplifications, ligand‐binding domain missense mutations, and intronic structural rearrangements can all drive resistance to approved AR pathway inhibitors and their detection via tissue or liquid biopsy is linked to clinical outcomes. With an increasingly crowded treatment landscape, there is hope that AR genomic alterations can act as prognostic and/or predictive biomarkers to guide patient management. Methods In this review, we evaluate the current evidence for AR genomic alterations as clinical biomarkers in mCRPC, focusing on correlative studies that have used plasma circulating tumor DNA to characterize AR genotype. Results We highlight data that demonstrates the complexity of AR genotype within individual patients, and suggest that future studies should account for cancer clonal heterogeneity and variable tumor content in liquid biopsy samples. Given the potential for cooccurrence of multiple AR genomic alterations in the same or competing subclones of a patient, it is distinctly challenging to attribute blanket clinical significance to any individual alteration. This challenge is further complicated by the varied treatment exposures in contemporary patients, and the fact that AR genotype continues to evolve in the mCRPC setting across sequential lines of systemic therapy. Conclusions As treatment access and liquid biopsy technology continues to improve, we posit that real‐time measures of AR biology are likely to play a key role in emerging precision oncology strategies for metastatic prostate cancer.

show abstract

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Cited by 454 publications

References 30 publications

Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis

Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis

Emerging Biomarker-Guided Therapies in Prostate Cancer

Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer

Contact Info

Product

Resources

About